CathWorks FFRangio® System:
A New Era in Coronary Physiology

The FFRangio System combines artificial intelligence and advanced computational science to obtain physiologic information from routine angiograms to better inform treatment decisions. Now, interventional cardiologists in the cath lab can quickly get more insight with less hassle.

Discover FFRangio

About CathWorks

Our Mission

As a leader in digital health innovations, CathWorks is dedicated to partnering with physicians to improve the health of patients by transforming how cardiovascular disease is diagnosed and treated.

Our Investors

CathWorks is backed by a strong group of investing partners.

Our Partnerships

Our partnership with Medtronic underscores their commitment to investing in innovative technologies that support physicians and patients from diagnosis to treatment and CathWorks’ FFRangio® System’s potential to disrupt traditional FFR and revolutionize the management of coronary artery disease.

Our Latest News

PROVISION Study, First Ever Prospective RCT of CathWorks FFRangio Outcomes Compared to Invasive Wire-based Physiology in Japan, Meets its Primary Endpoint

October 27, 2024

Today at the Cardiovascular Research Foundation’s annual Transcatheter Cardiovascular Therapeutics (TCT) conference taking place at the Walter E. Washington Convention Center in Washington, DC, investigators from Gifu Heart Center and Fukuoka Sanno Hospital presented the…

CathWorks Announces Key Events for TCT 2024

October 25, 2024

CathWorks, a global leader in digital health innovations, announced today the schedule of key events for the company during the upcoming Cardiovascular Research Foundation’s annual Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference taking place October 27…

CathWorks Announces EU MDR Approval, Prominent Presence at EuroPCR and Full Launch of Co-promotion

May 13, 2024

CathWorks announced today that the CathWorks FFRangio® System is now approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR, and fulfills the requirements for CE marking (0344).

CathWorks Announces First Patient Enrolled in Global ALL-RISE Study

June 28, 2023

CathWorks announced today that the first patient has been enrolled in the Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment (ALL-RISE) Study.

Learn More

Clinical Studies

News & Insights

CathWorks Events

CathWorks FFRangio® System:
A New Era in Coronary Physiology

About CathWorks

Our Mission

Our Investors

Our Partnerships

Our Latest News

PROVISION Study, First Ever Prospective RCT of CathWorks FFRangio Outcomes Compared to Invasive Wire-based Physiology in Japan, Meets its Primary Endpoint

CathWorks Announces Key Events for TCT 2024

CathWorks Announces EU MDR Approval, Prominent Presence at EuroPCR and Full Launch of Co-promotion

CathWorks Announces First Patient Enrolled in Global ALL-RISE Study

Learn More

Regulatory Status

Contact CathWorks Today

CathWorks FFRangio® System: A New Era in Coronary Physiology

About CathWorks

Our Mission

Our Investors

Our Partnerships

Our Latest News

PROVISION Study, First Ever Prospective RCT of CathWorks FFRangio Outcomes Compared to Invasive Wire-based Physiology in Japan, Meets its Primary Endpoint

CathWorks Announces Key Events for TCT 2024

CathWorks Announces EU MDR Approval, Prominent Presence at EuroPCR and Full Launch of Co-promotion

CathWorks Announces First Patient Enrolled in Global ALL-RISE Study

Learn More

Regulatory Status

Contact CathWorks Today

CathWorks FFRangio® System:
A New Era in Coronary Physiology